Fasting mimicking diet in mice delays cancer growth and reduces immunotherapy-associated cardiovascular and systemic side effects.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
08 09 2023
08 09 2023
Historique:
received:
08
11
2022
accepted:
22
08
2023
medline:
11
9
2023
pubmed:
9
9
2023
entrez:
8
9
2023
Statut:
epublish
Résumé
Immune checkpoint inhibitors cause side effects ranging from autoimmune endocrine disorders to severe cardiotoxicity. Periodic Fasting mimicking diet (FMD) cycles are emerging as promising enhancers of a wide range of cancer therapies including immunotherapy. Here, either FMD cycles alone or in combination with anti-OX40/anti-PD-L1 are much more effective than immune checkpoint inhibitors alone in delaying melanoma growth in mice. FMD cycles in combination with anti-OX40/anti-PD-L1 also show a trend for increased effects against a lung cancer model. As importantly, the cardiac fibrosis, necrosis and hypertrophy caused by immune checkpoint inhibitors are prevented/reversed by FMD treatment in both cancer models whereas immune infiltration of CD3
Identifiants
pubmed: 37684243
doi: 10.1038/s41467-023-41066-3
pii: 10.1038/s41467-023-41066-3
pmc: PMC10491752
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5529Informations de copyright
© 2023. Springer Nature Limited.
Références
Admin, U. F. D. KEYTRUDA (pembrolizumab) injection, for intravenous use. (Prescrib. Inf., US Food Drug Admin., Silver Spring, MD., https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s066lbl.pdf , 2020).
Admin, U. F. D. Opdivo (nivolumab). (Drug. Inf., US Food Drug Admin., Silver Spring, MD., https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554 , 2019).
Admin, U. F. D. Yervoy (ipilimumab). (Drug. Inf.,US Food Drug Admin., Silver Spring, MD, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377 , 2019).
Eggermont, A. M. et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375, 1845–1855 (2016).
pubmed: 27717298
pmcid: 5648545
doi: 10.1056/NEJMoa1611299
Eggermont, A. M. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16, 522–530 (2015).
pubmed: 25840693
doi: 10.1016/S1470-2045(15)70122-1
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
pubmed: 20525992
pmcid: 3549297
doi: 10.1056/NEJMoa1003466
Larkin, J. et al. Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019).
pubmed: 31562797
doi: 10.1056/NEJMoa1910836
Motzer, R. J. et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).
pubmed: 26406148
pmcid: 5719487
doi: 10.1056/NEJMoa1510665
Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006–2017 (2015).
pubmed: 25891304
pmcid: 5744258
doi: 10.1056/NEJMoa1414428
Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
pubmed: 27718847
doi: 10.1056/NEJMoa1606774
Ribas, A. et al. Association of Pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315, 1600–1609 (2016).
pubmed: 27092830
doi: 10.1001/jama.2016.4059
Robert, C. et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
pubmed: 25891173
doi: 10.1056/NEJMoa1503093
Croft, M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 3, 609–620 (2003).
pubmed: 12974476
doi: 10.1038/nri1148
Pan, P. Y., Zang, Y., Weber, K., Meseck, M. L. & Chen, S. H. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol. Ther. 6, 528–536 (2002).
pubmed: 12377195
doi: 10.1006/mthe.2002.0699
Piconese, S., Valzasina, B. & Colombo, M. P. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 205, 825–839 (2008).
pubmed: 18362171
pmcid: 2292222
doi: 10.1084/jem.20071341
Valzasina, B. et al. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105, 2845–2851 (2005).
pubmed: 15591118
doi: 10.1182/blood-2004-07-2959
Watts, T. H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23, 23–68 (2005).
pubmed: 15771565
doi: 10.1146/annurev.immunol.23.021704.115839
Chen, W. et al. Identification of cutaneous immune-related adverse events by International Classification of Diseases codes and medication administration. JAAD Int. 9, 112–115 (2022).
pubmed: 36248205
pmcid: 9563326
doi: 10.1016/j.jdin.2022.08.001
Kalinich, M. et al. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. J. Immunother. Cancer 9, e001935 (2021).
pubmed: 33789879
pmcid: 8016099
doi: 10.1136/jitc-2020-001935
Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563–580 (2019).
pubmed: 31092901
doi: 10.1038/s41571-019-0218-0
Mahmood, S. S. et al. Myocarditis in patients treated with immune checkpoint inhibitors. J. Am. Coll. Cardiol. 71, 1755–1764 (2018).
pubmed: 29567210
pmcid: 6196725
doi: 10.1016/j.jacc.2018.02.037
Michel, L., Rassaf, T. & Totzeck, M. Cardiotoxicity from immune checkpoint inhibitors. Int. J. Cardiol. Heart Vasc. 25, 100420 (2019).
pubmed: 31517036
pmcid: 6736791
Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749–1755 (2016).
pubmed: 27806233
pmcid: 5247797
doi: 10.1056/NEJMoa1609214
Grabie, N., Lichtman, A. H. & Padera, R. T cell checkpoint regulators in the heart. Cardiovasc. Res. 115, 869–877 (2019).
pubmed: 30721928
pmcid: 6452292
doi: 10.1093/cvr/cvz025
Okazaki, T. et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med. 9, 1477–1483 (2003).
pubmed: 14595408
doi: 10.1038/nm955
Barik, S. New treatments for influenza. BMC Med. 10, 104 (2012).
pubmed: 22973873
pmcid: 3523090
doi: 10.1186/1741-7015-10-104
To, K. K. et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin. Infect. Dis. 50, 850–859 (2010).
pubmed: 20136415
doi: 10.1086/650581
Damjanovic, D., Small, C. L., Jeyanathan, M., McCormick, S. & Xing, Z. Immunopathology in influenza virus infection: uncoupling the friend from foe. Clin. Immunol. 144, 57–69 (2012).
pubmed: 22673491
doi: 10.1016/j.clim.2012.05.005
Peiris, J. S., Hui, K. P. & Yen, H. L. Host response to influenza virus: protection versus immunopathology. Curr. Opin. Immunol. 22, 475–481 (2010).
pubmed: 20594815
pmcid: 2927395
doi: 10.1016/j.coi.2010.06.003
Caffa, I. et al. Fasting-mimicking diet and hormone therapy induce breast cancer regression. Nature 583, 620–624 (2020).
pubmed: 32669709
pmcid: 7881940
doi: 10.1038/s41586-020-2502-7
Lee, C. et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci. Transl. Med. 4, 124ra127 (2012).
doi: 10.1126/scitranslmed.3003293
Nencioni, A., Caffa, I., Cortellino, S. & Longo, V. D. Fasting and cancer: molecular mechanisms and clinical application. Nat. Rev. Cancer 18, 707–719 (2018).
pubmed: 30327499
pmcid: 6938162
doi: 10.1038/s41568-018-0061-0
Raffaghello, L. et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc. Natl Acad. Sci. USA 105, 8215–8220 (2008).
pubmed: 18378900
pmcid: 2448817
doi: 10.1073/pnas.0708100105
Vernieri, C. et al. Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in patients with cancer. Cancer Discov. 12, 90–107 (2022).
pubmed: 34789537
doi: 10.1158/2159-8290.CD-21-0030
Weng, M. L. et al. Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Fdft1-mediated AKT/mTOR/HIF1alpha pathway suppression. Nat. Commun. 11, 1869 (2020).
pubmed: 32313017
pmcid: 7170903
doi: 10.1038/s41467-020-15795-8
Ajona, D. et al. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. Nat. Cancer 1, 75–85 (2020).
pubmed: 35121837
doi: 10.1038/s43018-019-0007-9
Cortellino, S. et al. Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects. Cell Rep. 40, 111256 (2022).
pubmed: 36001966
doi: 10.1016/j.celrep.2022.111256
Di Biase, S. et al. Fasting-mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity. Cancer Cell 30, 136–146 (2016).
pubmed: 27411588
pmcid: 5388544
doi: 10.1016/j.ccell.2016.06.005
Pietrocola, F. et al. Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer Cell 30, 147–160 (2016).
pubmed: 27411589
pmcid: 5715805
doi: 10.1016/j.ccell.2016.05.016
Brandhorst, S. et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan. Cell Metab. 22, 86–99 (2015).
pubmed: 26094889
pmcid: 4509734
doi: 10.1016/j.cmet.2015.05.012
Cheng, C. W. et al. Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression. Cell Stem Cell 14, 810–823 (2014).
pubmed: 24905167
pmcid: 4102383
doi: 10.1016/j.stem.2014.04.014
Longo, V. D. & Cortellino, S. Fasting, dietary restriction, and immunosenescence. J. Allergy Clin. Immunol. 146, 1002–1004 (2020).
pubmed: 32853639
doi: 10.1016/j.jaci.2020.07.035
Wei, M. et al. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci. Transl. Med. 9, eaai8700 (2017).
pubmed: 28202779
pmcid: 6816332
doi: 10.1126/scitranslmed.aai8700
Collins, N. et al. The bone marrow protects and optimizes immunological memory during dietary restriction. Cell 178, 1088–1101.e1015 (2019).
pubmed: 31442402
pmcid: 6818271
doi: 10.1016/j.cell.2019.07.049
Jordan, S. et al. Dietary intake regulates the circulating inflammatory monocyte pool. Cell 178, 1102–1114.e1117 (2019).
pubmed: 31442403
pmcid: 7357241
doi: 10.1016/j.cell.2019.07.050
Choi, I. Y. et al. A diet mimicking fasting promotes regeneration and reduces autoimmunity and multiple sclerosis symptoms. Cell Rep. 15, 2136–2146 (2016).
pubmed: 27239035
pmcid: 4899145
doi: 10.1016/j.celrep.2016.05.009
Rangan, P. et al. Fasting-mimicking diet modulates microbiota and promotes intestinal regeneration to reduce inflammatory bowel disease pathology. Cell Rep. 26, 2704–2719.e2706 (2019).
pubmed: 30840892
pmcid: 6528490
doi: 10.1016/j.celrep.2019.02.019
Messenheimer, D. J. et al. Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40. Clin. Cancer Res. 23, 6165–6177 (2017).
pubmed: 28855348
pmcid: 5641261
doi: 10.1158/1078-0432.CCR-16-2677
Quagliariello, V. et al. NLRP3 as putative marker of ipilimumab-induced cardiotoxicity in the presence of hyperglycemia in estrogen-responsive and triple-negative breast cancer cells. Int. J. Mol. Sci. 21, 7802 (2020).
pubmed: 33096896
pmcid: 7589802
doi: 10.3390/ijms21207802
Quagliariello, V. et al. Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways. Front. Cardiovasc. Med. 9, 930797 (2022).
pubmed: 36158826
pmcid: 9505026
doi: 10.3389/fcvm.2022.930797
Colazzo, F., Gelosa, P., Tremoli, E., Sironi, L. & Castiglioni, L. Role of the cysteinyl leukotrienes in the pathogenesis and progression of cardiovascular diseases. Mediators Inflamm. 2017, 2432958 (2017).
pubmed: 28932020
pmcid: 5592403
doi: 10.1155/2017/2432958
Hafstrom, I., Ringertz, B., Gyllenhammar, H., Palmblad, J. & Harms-Ringdahl, M. Effects of fasting on disease activity, neutrophil function, fatty acid composition, and leukotriene biosynthesis in patients with rheumatoid arthritis. Arthritis Rheum. 31, 585–592 (1988).
pubmed: 2837251
doi: 10.1002/art.1780310502
De Gomez Dumm, I. N., De Alaniz, M. J. & Brenner, R. R. Effect of diet on linoleic acid desaturation and on some enzymes of carbohydrate metabolism. J. Lipid Res. 11, 96–101 (1970).
pubmed: 5418484
doi: 10.1016/S0022-2275(20)42999-2
Liu, S. et al. Cardiovascular toxicity with PD-1/PD-L1 inhibitors in cancer patients: a systematic review and meta-analysis. Front. Immunol. 13, 908173 (2022).
pubmed: 35880172
pmcid: 9307961
doi: 10.3389/fimmu.2022.908173
Salem, J. E. et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 19, 1579–1589 (2018).
pubmed: 30442497
pmcid: 6287923
doi: 10.1016/S1470-2045(18)30608-9
Wang, Y. et al. Adverse event reporting quality in cancer clinical trials evaluating immune checkpoint inhibitor therapy: a systematic review. Front. Immunol. 13, 874829 (2022).
pubmed: 35874673
pmcid: 9301013
doi: 10.3389/fimmu.2022.874829
Duhen, R. et al. Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nat. Commun. 12, 1047 (2021).
pubmed: 33594075
pmcid: 7886909
doi: 10.1038/s41467-021-21383-1
Glisson, B. S. et al. Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors. Clin. Cancer Res. 26, 5358–5367 (2020).
pubmed: 32816951
doi: 10.1158/1078-0432.CCR-19-3070
Gutierrez, M. et al. OX40 agonist BMS-986178 alone or in combination with Nivolumab and/or Ipilimumab in patients with advanced solid tumors. Clin Cancer Res. 27, 460–472 (2021).
pubmed: 33148673
doi: 10.1158/1078-0432.CCR-20-1830
Wang, R. et al. An integrative approach to inform optimal administration of OX40 agonist antibodies in patients with advanced solid tumors. Clin. Cancer Res. 25, 6709–6720 (2019).
pubmed: 31573956
doi: 10.1158/1078-0432.CCR-19-0526
Bergendahl, M., Vance, M. L., Iranmanesh, A., Thorner, M. O. & Veldhuis, J. D. Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. J. Clin. Endocrinol. Metab. 81, 692–699 (1996).
pubmed: 8636290
Carbone, A. et al. Takotsubo cardiomyopathy as epiphenomenon of cardiotoxicity in patients with cancer: a meta-summary of case reports. J. Cardiovasc. Pharmacol. 78, e20–e29 (2021).
pubmed: 34001727
doi: 10.1097/FJC.0000000000001026
Quagliariello, V. et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc. Diabetol. 20, 150 (2021).
pubmed: 34301253
pmcid: 8305868
doi: 10.1186/s12933-021-01346-y
Annie, F. H., Alkhaimy, H., Nanjundappa, A. & Elashery, A. Association between myocarditis and mortality in COVID-19 patients in a large registry. Mayo Clin. Proc. Innov. Qual. Outcomes 6, 114–119 (2022).
pubmed: 34977468
doi: 10.1016/j.mayocpiqo.2021.12.006
Witberg, G. et al. Myocarditis after Covid-19 vaccination in a large health care organization. N. Engl. J. Med. 385, 2132–2139 (2021).
pubmed: 34614329
doi: 10.1056/NEJMoa2110737
Guo, T. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 5, 811–818 (2020).
pubmed: 32219356
doi: 10.1001/jamacardio.2020.1017
Basso, C. et al. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur. Heart. J. 41, 3827–3835 (2020).
pubmed: 32968776
doi: 10.1093/eurheartj/ehaa664
Siripanthong, B. et al. Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm 17, 1463–1471 (2020).
pubmed: 32387246
pmcid: 7199677
doi: 10.1016/j.hrthm.2020.05.001
Terme, M. et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 71, 5393–5399 (2011).
pubmed: 21724589
doi: 10.1158/0008-5472.CAN-11-0993